Core tip: GE announced its performance on Oct. 16 for Q3, while Philips announced it on Oct. 26. Siemens fiscal year is a bit of special starting from Oct. 1 ending to Sep. 30, so it announced on Nov. 12 was Q4 performance. Mindray just announced its Q3 performance on Nov. 13 hence we put it together with GPS to help you to learn the three giants further through analyzing and comparing.

1. Revenue and profits

We can see from below table that the performance for the 3 giants in Q3 was barely satisfactory due to the reason of global economic downturn. The three giants cannot just stand alone and keep out of the affair because of their global business.

Table1: Revenue and profit contrast between GPS and Mindray(GE & Mindray` s unit is million US dollar, the other two is million euro)

2. Regional performance

The three giants performed well in developed countries like US and Europe but appeared negative growth in new emerged market impacting by economy and exchanging rate. Especially in China, Philips and Siemens kept double digit negative growth and GE just recovered flat.

Table2: Performance contrast between GPS and Mindray ((GE & Mindray` s unit is million US dollar, the other two is million euro)

3.Business performance in medical treatment unit

1. GE Healthcare with $4.5 billion orders declined 4%. From the regional performance, the US declined 1%, 5% in Europe, and kept flat in China but increased 15% in the Middle East. For the product line, the order in medical system declined 7%. The US CT and MRI increased 10% and 15% separately, but fell off in X-ray. In Europe, 5 quarters increasing up to 7% and the Middle East up to 22%. Impacted by the reduced biding in Chinese government, it went down 14%, even though business in Chinese private hospitals have double digit growth but still lesser comparing with public hospitals.
CF in GE indicated that over 74% of medical revenue came from developed countries like US, European countries and Japan while China medical market keeps growing, after all it has huge population keeping building hospitals with very good private market growth between 15-20%.

2. Philips Healthcare:
Before analyzing Philips, we have to mention 2 big events: one is the former CEO who himself did not predict quit to the other company before 2 weeks that Philips announced its performance. The other is they planned to make the illuminating business (€1.83 billion revenue in Q3 occupied 31.3%) independent or be sold in the first half year 2016, in that case the proportion of medical treatment business (now is 45%) will be higher.
Philips senior layer satisfies the medical business performance and they will invest more in individual treatment such as HealthSuit digital platform, Philips Watch, etc. Mass DOM, health information system, solution and after-sale service obtained the median growth, while the patients monitoring held the line with last year. The company announced that a serious of sleep treating product has been developed under the basic of Respironis especially conform to patients` used face mask opening the distance with its competitors. In the aspect of cardiac intervention therapy, it has cooperated with Cathrina hospital Holland biggest angiocarpy medical centre and purchased Blue Jay consulting company which supplied counsel to emergency department in hospital.

3. Siemens Healthcare: Although Siemens impacted by “Patent Lawsuit Event”, “Distributor Lawsuit Event” and “Employee Strike Event” but its overall business still keeps  going. The medical individual scheme develops smoothly and the new organization structure emerged at the proper time. The previous 12 units, 3 groups, 13 regions and customer solutions groups will be integrated into 6 regions and 6 business fields. Its MRI and CT ranks first in the world, after purchased the IVD part from Bayer, Dade Berhring and DPC, it once approached to Roche ranks second, hence we need to pay attention to its future trend in medical business performance.